Patents by Inventor Craig S. Siegel
Craig S. Siegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10954230Abstract: This invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: GrantFiled: February 14, 2020Date of Patent: March 23, 2021Assignee: GENZYME CORPORATIONInventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
-
Publication number: 20200181137Abstract: This invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: ApplicationFiled: February 14, 2020Publication date: June 11, 2020Inventors: Craig S. SIEGEL, Rayomand GIMI, Michael REARDON, Jin ZHAO
-
Patent number: 10604518Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: GrantFiled: August 1, 2018Date of Patent: March 31, 2020Assignee: GENZYME CORPORATIONInventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
-
Publication number: 20190031652Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: ApplicationFiled: August 1, 2018Publication date: January 31, 2019Applicant: Genzyme CorporationInventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
-
Patent number: 10065949Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: GrantFiled: May 12, 2017Date of Patent: September 4, 2018Assignee: GENZYME CORPORATIONInventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
-
Publication number: 20170334903Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: ApplicationFiled: May 12, 2017Publication date: November 23, 2017Applicant: Genzyme CorporationInventors: Craig S. SIEGEL, Rayomand GIMI, Michael REARDON, Jin ZHAO
-
Patent number: 9682975Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: GrantFiled: March 13, 2014Date of Patent: June 20, 2017Assignee: Genzyme CorporationInventors: Craig S. Siegel, Rayomand Gimi, Michael Reardon, Jin Zhao
-
Patent number: 9518049Abstract: The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: GrantFiled: March 14, 2014Date of Patent: December 13, 2016Assignee: GENZYME CORPORATIONInventors: Craig S. Siegel, Jin Zhao
-
Publication number: 20160039805Abstract: The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl(2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 11, 2016Applicant: Genzyme CorporationInventors: Craig S. SIEGEL, Jin ZHAO
-
Publication number: 20160039806Abstract: The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Type: ApplicationFiled: March 13, 2014Publication date: February 11, 2016Inventors: Craig S. SIEGEL, Rayomand GIMI, Michael REARDON, Jin ZHAO
-
Patent number: 6383814Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: January 11, 1999Date of Patent: May 7, 2002Assignee: Genzyme CorporationInventors: Edward R. Lee, David J. Harris, Craig S. Siegel, Mathieu B. Lane, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K Scheule, Nelson S. Yew
-
Publication number: 20020013282Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.Type: ApplicationFiled: October 5, 1998Publication date: January 31, 2002Inventors: JOHN MARSHALL, DAVID J. HARRIS, EDWARD R. LEE, CRAIG S. SIEGEL, SIMON J. EASTMAN, CHAU-DUNG CHANG, RONALD K. SCHEULE, SENG H. CHENG
-
Patent number: 6331524Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: April 7, 1997Date of Patent: December 18, 2001Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, David J. Harris, Edward R. Lee, Craig S. Siegel, Chau-Dung Chang, S. Catherine Hubbard, Duane E. Johnson, Daniel C. Maneval, H. Michael Shepard, Richard J. Gregory
-
Patent number: 6071890Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: October 19, 1995Date of Patent: June 6, 2000Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel
-
Patent number: 5952516Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 8, 1997Date of Patent: September 14, 1999Assignee: Genzyme CorporationInventors: Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5948767Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: July 12, 1996Date of Patent: September 7, 1999Assignee: Genzyme CorporationInventors: Ronald K. Scheule, Rebecca G. Bagley, Simon J. Eastman, Seng H. Cheng, John Marshall, Nelson S. Yew, David J. Harris, Edward R. Lee, Craig S. Siegel, Chau-Dung Chang, S. Catherine Hubbard
-
Patent number: 5948925Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 6, 1997Date of Patent: September 7, 1999Assignee: Genzyme CorporationInventors: Mikaela N. Keynes, Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5942634Abstract: Cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Type: GrantFiled: May 9, 1997Date of Patent: August 24, 1999Assignee: Genzyme CorporationInventors: Craig S. Siegel, Edward R. Lee, David J. Harris
-
Patent number: 5939401Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional protons, i.e., it is not fully protonated. For purposes of this invention, cationic amphiphiles may be considered to encompass four general categories: (A) T-shaped/steroid-based amphiphiles; (B) T-shaped/non steroid-based amphiphiles; (C) non T-shaped/steroid based amphiphiles and (D) non T-shaped/non steroid-based amphiphiles.Type: GrantFiled: July 15, 1996Date of Patent: August 17, 1999Assignee: Genzyme CorporationInventors: John Marshall, David J. Harris, Edward R. Lee, Craig S. Siegel, Simon J. Eastman, Chau-Dung Chang, Ronald K. Scheule, Seng H. Cheng
-
Patent number: 5935936Abstract: Novel compositions are provided. Typically, the compositions comprise one or more neutral co-lipids and also a cationic amphiphile. Therapeutic compositions are prepared according to the practice of the invention by contacting a therapeutically active molecule with a dispersion of neutral co-lipid(s) and amphiphile(s).Type: GrantFiled: June 3, 1996Date of Patent: August 10, 1999Assignees: Genzyme Corporation, University of IowaInventors: Allen J. Fasbender, Michael J. Welsh, Craig S. Siegel, Edward R. Lee, Chau-Dung Chang, John Marshall, Seng H. Cheng, David J. Harris, Simon J. Eastman, Shirley C. Hubbard, Mathieu B. Lane, Eric A. Rowe, Ronald K. Scheule, Nelson S. Yew